Premium
Safety and efficacy of 2‐weekly cabazitaxel in metastatic castration‐resistant prostate cancer
Author(s) -
ClémentZhao Alice,
Auvray Marie,
Aboudagga Hail,
BlancDurand Félix,
Angelergues Antoine,
Vano Yann Alexandre,
Mercier Florence,
El Awadly Nader,
Verret Benjamin,
Thibault Constance,
Oudard Stéphane
Publication year - 2018
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/bju.13855
Subject(s) - cabazitaxel , medicine , docetaxel , prostate cancer , regimen , abiraterone acetate , febrile neutropenia , neutropenia , oncology , phases of clinical research , toxicity , urology , chemotherapy , cancer , androgen deprivation therapy
Objectives To evaluate the safety and efficacy of a 2‐weekly cabazitaxel schedule in patients with metastatic castration‐resistant prostate cancer ( mCRPC ). Materials and methods During the period October 2013 to February 2016, 43 patients with mCRPC were treated with cabazitaxel (16 mg/m 2 , on days 1 and 15 of a 4‐week cycle) together with prophylactic granulocyte colony‐stimulating factor (G‐ CSF ). The safety profile and efficacy (prostate‐specific antigen [ PSA ] response; biological, clinical or radiological progression‐free survival [ PFS ] and overall survival [ OS ]) of the treatment were analysed. Results All patients had received prior docetaxel and 79.1% abiraterone acetate. At inclusion, 46.5% were aged >70 years and 27.9% had an Eastern Cooperative Oncology Group performance status ≥2. Six patients stopped treatment because of toxicity. Grade ≥3 toxicities were: asthenia (16.3%); neutropenia (11.6%); thrombocytopenia (9.3%); diarrhoea (7%), anaemia (4.7%), febrile neutropenia (4.7%) and haematuria (2.3%). In all, 52.4% achieved a ≥30% PSA response and 40.5% had a ≥50% PSA response. The median OS was 15.2 months. Conclusion This prospective pilot study suggests that cabazitaxel 16 mg/m² given 2‐weekly has a manageable toxicity profile in docetaxel‐ and abiraterone acetate‐pretreated patients with mCRPC . A prospective phase III trial comparing this regimen with the standard cabazitaxel regimen is planned to confirm these results.